Alkermes (NASDAQ:ALKS) Research Coverage Started at Truist Financial

Posted by Stanley Muller on Oct 19th, 2026

Truist Financial began coverage on shares of Alkermes (NASDAQ:ALKS – Free Report) in a research report released on Friday morning, Marketbeat.com reports. The firm issued a buy rating and a $55.00 price objective on the stock.

Several other research firms have also weighed in on ALKS. Wells Fargo & Company raised their price objective on shares of Alkermes from $44.00 to $65.00 and gave the company an “overweight” rating in a research report on Monday, June 29th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $56.00 price objective on shares of Alkermes in a research note on Tuesday, September 22nd. Piper Sandler reiterated an “overweight” rating and issued a $65.00 target price (up from $43.00) on shares of Alkermes in a report on Tuesday, July 28th. TD Cowen reiterated a “buy” rating on shares of Alkermes in a report on Monday, September 21st. Finally, Bank of America reissued an “underperform” rating on shares of Alkermes in a research note on Monday, June 29th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $54.47.

View Our Latest Analysis on ALKS

Alkermes Price Performance

NASDAQ:ALKS opened at $41.22 on Friday. The business’s 50-day moving average price is $45.02 and its 200 day moving average price is $43.72. The firm has a market cap of $6.92 billion, a P/E ratio of 108.48 and a beta of 0.32. Alkermes has a 52-week low of $27.00 and a 52-week high of $55.67. The company has a quick ratio of 1.85, a current ratio of 2.30 and a debt-to-equity ratio of 0.82.

Insider Buying and Selling

In other news, EVP Craig C. Hopkinson sold 9,000 shares of the business’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $48.58, for a total transaction of $437,220.00. Following the sale, the executive vice president directly owned 69,389 shares of the company’s stock, valued at $3,370,917.62. The trade was a 11.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP David Gaffin sold 2,034 shares of the business’s stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $41.03, for a total value of $83,455.02. Following the sale, the executive vice president directly owned 221,388 shares in the company, valued at $9,083,549.64. This trade represents a 0.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 76,150 shares of company stock valued at $3,752,181. Insiders own 4.59% of the company’s stock.

Institutional Trading of Alkermes

Several institutional investors and hedge funds have recently bought and sold shares of ALKS. Versant Capital Management Inc raised its holdings in shares of Alkermes by 33.9% during the second quarter. Versant Capital Management Inc now owns 1,445 shares of the company’s stock valued at $76,000 after acquiring an additional 366 shares during the period. GAMMA Investing LLC lifted its position in shares of Alkermes by 5.7% in the 3rd quarter. GAMMA Investing LLC now owns 7,090 shares of the company’s stock valued at $287,000 after acquiring an additional 385 shares in the last quarter. Sequoia Financial Advisors LLC boosted its stake in Alkermes by 4.8% in the 1st quarter. Sequoia Financial Advisors LLC now owns 9,272 shares of the company’s stock worth $328,000 after purchasing an additional 422 shares during the period. Arizona State Retirement System boosted its stake in Alkermes by 1.1% in the 2nd quarter. Arizona State Retirement System now owns 43,580 shares of the company’s stock worth $2,283,000 after purchasing an additional 494 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. boosted its stake in Alkermes by 4.0% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 13,900 shares of the company’s stock worth $492,000 after purchasing an additional 530 shares during the period. Institutional investors and hedge funds own 95.21% of the company’s stock.

About Alkermes

(Get Free Report)

Alkermes plc is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system diseases. The company’s portfolio addresses conditions including addiction, schizophrenia, bipolar disorder and amyotrophic lateral sclerosis (ALS), with an emphasis on long-acting injectable, extended-release and other drug-delivery technologies.

Its marketed products include Vivitrol, an extended-release injectable formulation of naltrexone used to treat alcohol dependence and prevent opioid dependence relapse; Aristada, a long-acting injectable formulation of aripiprazole lauroxil for the treatment of schizophrenia in adults; Lybalvi, an oral combination of olanzapine and samidorphan for schizophrenia and bipolar I disorder; and Exservan, an oral film formulation of riluzole for ALS.

Founded in 1987, Alkermes is headquartered in Dublin, Ireland, with operations and corporate offices in the United States, including Waltham, Massachusetts.